We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · May 10, 2021

Dapagliflozin Add-On Therapy vs Insulin Dose Escalation for Uncontrolled Insulin-Treated T2D

Diabetes Research and Clinical Practice

 

Additional Info

Diabetes Research and Clinical Practice
Comparison Between Dapagliflozin Add-On Therapy and Insulin Dose Escalation in Patients With Uncontrolled Type 2 Diabetes Treated With Insulin
Diabetes Res. Clin. Pract. 2021 Apr 29;[EPub Ahead of Print], Y Shin, H Choi, S Lim

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading